Call Us @ 0172 - 4680800 | [email protected] | NETWORKS | NSE - BSE

The Global Business Unit (GBU) of Ind-Swift Ltd was started in 2007. Through this Global Business Unit it exports its products to over 50 countries.

The GBU Facility is compliant to the GMP specifications of MHRA (UK), TGA (Australia). It has got approval of various drug authorities, such as:

  • MHRA (UK).
  • TGA (Australia).
  • WHO (Geneva).
  • MOH (UAE).
  • TFDA (Tanzania).
  • NDA (Uganda).
  • DACA(Ethiopia).
  • Dar-Al- Dawa DAD (Jordan).
  • ITOCHU (Japan).
  • Ind-Swift develops and out licenses its products to UK, Europe, Canada and Australia with leading generic partners such as TEVA, Mylan, Actavis, Stada and Ratiopharm.
  • Ind-Swift has filed more than 1000 dossiers in several countries.
  • Presently business negotiations are under process in Russia, Philippines, Taiwan, Afghanistan, Malaysia, Costa Rica, Panama, Honduras, Venezuela, Peru, Guyana, Jamaica and Serbia.
  • Ind-Swift is also involved in CRAMS (Contract Research & Manufacturing Services)